Alamar Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

ALMR$31.50-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)

	Nine Months Ended September 30,
	2026	2025
Cash flows from operating activities:
Net loss	$(47,866)	$(22,683)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	3,725	2,790
Stock-based compensation	8,663	2,004
Accretion and amortization of premiums and discounts on investments, net	(561)	(145)
Loss on remeasurement of convertible notes	9,971	—
Convertible note issuance costs included in net loss	361	—
Unrealized foreign exchange loss (gain)	303	(167)
Non-cash operating lease costs	1,781	1,451
Amortization of debt issuance costs	203	125
Change in fair value of warrant liabilities	117	31
Provision for expected credit losses	118	—
Changes in assets and liabilities:
Accounts receivable	(9,143)	(3,805)
Inventory	(17,196)	(18,854)
Contract assets	—	69
Net investment in sales-type lease	—	261
Prepaid expenses and other current assets	(2,646)	(3,583)
Other noncurrent assets	(447)	(28)
Accounts payable	9,290	1,989
Operating lease liabilities	(1,086)	(1,461)
Accrued expenses and other liabilities	(1,988)	2,917
Net cash used in operating activities	(46,401)	(39,089)
Cash flows from investing activities:
Purchases of short-term investments	(124,663)	(7,417)
Maturities of short-term investments	20,000	60,000
Purchases of property and equipment	(4,705)	(2,528)
Capitalized software development costs	(466)	(900)
Net cash (used in) provided by investing activities	(109,834)	49,155
Cash flows from financing activities:
Proceeds from issuance of common stock in connection with IPO, net of underwriting costs	204,542	—
Proceeds from term loan	—	10,000
Payment of third-party IPO costs	(6,150)	—
Proceeds from issuance of convertible notes	56,500	—
Repayment of borrowings under the credit facility	(10,000)	—
Payment of third-party debt issuance costs	(443)	(61)
Proceeds from issuance of common stock upon exercise of stock options	3,304	869
Net cash provided by financing activities	247,753	10,808
Effect of exchange rate changes on cash and cash equivalents, and restricted cash	12	—
Net increase in cash, cash equivalents and restricted cash	91,530	20,874
Cash, cash equivalents and restricted cash at beginning of period	34,909	31,677
Cash, cash equivalents and restricted cash at end of period	$126,439	$52,551
Supplemental disclosure of cash-flow information:
Cash paid for interest	$563	$9
Noncash investing and financing items:
Conversion of convertible preferred stock to common stock	$234,996	$—
Conversion of convertible notes to common stock	$66,471	$—
Reclassification of deferred offering costs to additional paid-in capital upon IPO	$6,705	$—
Vesting of early exercised stock options	$358	$11
Right-of-use assets obtained in exchange for new operating lease liabilities	$11,873	$462
Vesting of common stock warrants issued in connection with term loans	$—	$103
Conversion of preferred stock warrants to common stock warrants	$364	$—
Inventory transferred to property and equipment	$2,171	$169
Fixed assets transferred to inventory	$712	$—
Property and equipment included in accounts payable and accrued liabilities	$1,793	$228

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.